MARKET

ETON

ETON

Eton Pharmaceuticals
NASDAQ
2.100
-0.020
-0.94%
After Hours: 2.140 +0.04 +1.90% 16:02 09/30 EDT
OPEN
2.150
PREV CLOSE
2.120
HIGH
2.150
LOW
2.070
VOLUME
64.17K
TURNOVER
0
52 WEEK HIGH
6.72
52 WEEK LOW
1.950
MARKET CAP
53.12M
P/E (TTM)
-4.4426
1D
5D
1M
3M
1Y
5Y
Eton Pharmaceuticals, GeoVax Labs And 2 Other Penny Stocks Insiders Are Aggressively Buying
The Nasdaq Composite dropped by around 200 points on Friday. Investors, meanwhile, focused on some notable insider trades. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
Benzinga · 6d ago
HC Wainwright & Co. Maintains Buy on Eton Pharmaceuticals, Raises Price Target to $10
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Eton Pharmaceuticals (NASDAQ:ETON) with a Buy and raises the price target from $9 to $10.
Benzinga · 6d ago
--HC Wainwright Adjusts Eton Pharmaceuticals' Price Target to $10 From $9, Keeps Buy Rating
--HC Wainwright Adjusts Eton Pharmaceuticals' Price Target to $10 From $9, Keeps Buy Rating
MT Newswires · 6d ago
Eton Pharmaceuticals acquires FDA-approved rare disease product betaine anhydrous
Seekingalpha · 09/13 14:46
BRIEF-Eton Pharmaceuticals Announces Acquisition Of FDA-Approved Rare Disease Product
BRIEF-Eton Pharmaceuticals Announces Acquisition Of FDA-Approved Rare Disease Product
Reuters · 09/13 13:32
Eton Pharmaceuticals Adds FDA-Approved Rare Disease Product to Metabolic Genetics Portfolio
Eton Pharmaceuticals Adds FDA-Approved Rare Disease Product to Metabolic Genetics Portfolio
MT Newswires · 09/13 09:54
Eton Pharmaceuticals to Present at the H.C. Wainwright 24th Annual Global Investment Conference
DEER PARK, Ill., Aug. 30, 2022 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals (“Eton” or “the Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that Sean Brynjel...
GlobeNewswire · 08/30 20:05
Eton hits 52-week low as court invalidates patents for generic Cysteine Injection
The shares of the commercial-stage biopharma Eton Pharmaceuticals (NASDAQ:<a href="https://seekingalpha.com/symbol/ETON?utm_medium=referral&utm_source=webull.com" title="Eton Pharmaceuticals, Inc." target=...
Seekingalpha · 08/16 18:55
More
About ETON
Eton Pharmaceuticals, Inc. is a pharmaceutical company focused on developing and commercializing treatments for rare diseases. The Company is primarily focused on hospital injectable and pediatric rare disease products. The Company’s product portfolio includes Orphan Drugs and Royalty Products. The orphan drug products include Alkindi Sprinkle (hydrocortisone granules), Carglumic Acid tablets, Dehydrated Alcohol Injection, and Zeneo Hydrocortisone Autoinjector. The Company's royalty products category includes Alaway Preservative Free (ketotifen fumarate) and Neurology Oral Liquids. The Company's neurology oral liquid products include EPRONTIA (topiramate oral solution), Zonisamide Oral Suspension, and Lamotrigine for Oral Suspension. The Company’s solutions range includes from early clinical-stage to commercial stage, including research and development (R&D) formulations, as well as clinical research services. The Company has an interest in betaine anhydrous for oral solution.

Webull offers kinds of Eton Pharmaceuticals Inc stock information, including NASDAQ:ETON real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ETON stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ETON stock methods without spending real money on the virtual paper trading platform.